Ace­po­di­a's off-the-shelf cell ther­a­pies get an­oth­er $100M for on­col­o­gy tri­als

Cal­i­for­nia and Taipei biotech Ace­po­dia has lined up an­oth­er six-fig­ure fund­ing round to take its off-the-shelf cell ther­a­pies for­ward.

Spun out of No­bel lau­re­ate Car­olyn Bertozzi’s lab and found­ed in 2017 by ex-Juno EVP Patrick Yang and UC Berke­ley cell bi­ol­o­gist Son­ny Hsiao, the biotech has now raised a to­tal of $259 mil­lion thanks to a $100 mil­lion Se­ries D dis­closed Tues­day morn­ing.

The round fol­lows a $109 mil­lion Se­ries C in De­cem­ber 2021, at which point Yang told End­points News the start­up would mon­i­tor the pub­lic mar­kets and con­sid­er whether to go pub­lic in 2022. But as the mar­kets cooled fol­low­ing a pan­dem­ic high, the biotech chose to go with an­oth­er pri­vate round, led by Dig­i­tal Mo­bile Ven­ture, to bankroll clin­i­cal tri­als of al­lo­gene­ic cell ther­a­pies in non-Hodgkin lym­phoma and EGFR-ex­press­ing sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER